TYLER, Texas, June 1, 2006 (PRIMEZONE) -- Biogenerics Limited (Pink Sheets:BIGN) announced today that its 50% owned subsidiary, WW Oil and Gas, has authorized management to issue a Letter of Intent (LOI) for the purchase of 1,000 acres of oil/gas lease land. The lease land will include 48 producing gas wells generating 1,200 mcf/day of gas averaging 25 bbls/oil per day in condensate quality.
The transaction includes a 35-mile pipeline with all right-of-ways which connects to a major trunk line for the sale of the operation's daily gas production. The pipeline is also used to collect, on a fee basis, gas from six other producing gas fields in the area.
James Lancaster, Biogenerics' CEO stated, "The monthly revenue stream is estimated to be over $270,000 per month from this property. Upon completion, the deal will provide the personnel to manage, drill and rework the other well sites on these properties which will in turn maximize the production revenue of future explorations projects."
Website: http:/www.bignltd.com
About Biogenerics Limited
Biogenerics is a diversified investment venture capital firm focused on exploiting and distributing domestic oil and gas reserves. Biogenerics also has joint venture activities with Tyche Energy and Hydroslotter Corporation.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.